NASDAQ:EXEL
$19.19
(
-1.03%
)
Friday, 2nd Jun 2023
Exelixis Stock Price (Quote)
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $18.52 | $20.11 | Friday, 2nd Jun 2023 EXEL stock ended at $19.19. This is 1.03% less than the trading day before Thursday, 1st Jun 2023. During the day the stock fluctuated 2.07% from a day low at $19.11 to a day high of $19.51. |
| 90 days | $16.15 | $20.56 | |
| 52 weeks | $14.87 | $22.47 |
Historical Exelixis prices
| Date | Open | High | Low | Close | Volume |
| 2023-06-02 | $19.46 | $19.51 | $19.11 | $19.19 | 1 684 927 |
| 2023-06-01 | $19.35 | $19.59 | $19.23 | $19.39 | 1 700 443 |
| 2023-05-31 | $19.06 | $19.38 | $19.00 | $19.28 | 2 944 197 |
| 2023-05-30 | $19.00 | $19.24 | $18.95 | $19.01 | 1 648 304 |
| 2023-05-26 | $19.18 | $19.30 | $18.97 | $19.13 | 1 568 237 |
| 2023-05-25 | $19.30 | $19.30 | $18.75 | $19.03 | 2 220 542 |
| 2023-05-24 | $19.32 | $19.61 | $19.21 | $19.33 | 2 737 501 |
| 2023-05-23 | $19.76 | $19.79 | $19.30 | $19.33 | 2 114 610 |
| 2023-05-22 | $19.87 | $20.11 | $19.73 | $19.77 | 1 932 018 |
| 2023-05-19 | $19.83 | $19.96 | $19.76 | $19.79 | 1 829 511 |
| 2023-05-18 | $19.22 | $19.76 | $19.13 | $19.73 | 2 383 753 |
| 2023-05-17 | $19.14 | $19.35 | $18.90 | $19.25 | 1 959 725 |
| 2023-05-16 | $19.23 | $19.47 | $19.12 | $19.13 | 1 989 945 |
| 2023-05-15 | $19.20 | $19.62 | $19.20 | $19.50 | 1 855 368 |
| 2023-05-12 | $19.39 | $19.41 | $19.11 | $19.18 | 1 277 939 |
| 2023-05-11 | $19.29 | $19.45 | $19.15 | $19.35 | 2 468 416 |
| 2023-05-10 | $19.23 | $19.57 | $18.52 | $19.38 | 4 412 938 |
| 2023-05-09 | $18.94 | $19.32 | $18.90 | $19.23 | 2 393 038 |
| 2023-05-08 | $19.40 | $19.40 | $19.01 | $19.03 | 2 014 979 |
| 2023-05-05 | $19.49 | $19.62 | $19.18 | $19.48 | 1 873 767 |
| 2023-05-04 | $19.26 | $19.70 | $19.22 | $19.48 | 2 575 557 |
| 2023-05-03 | $18.86 | $19.42 | $18.76 | $19.21 | 2 961 690 |
| 2023-05-02 | $18.74 | $18.99 | $18.66 | $18.83 | 2 835 145 |
| 2023-05-01 | $18.30 | $18.91 | $18.21 | $18.83 | 2 578 599 |
| 2023-04-28 | $18.10 | $18.53 | $18.08 | $18.30 | 2 421 959 |
| 2023-04-27 | $18.42 | $18.42 | $18.09 | $18.17 | 2 245 860 |
| 2023-04-26 | $18.71 | $18.78 | $18.29 | $18.45 | 1 962 708 |
| 2023-04-25 | $18.77 | $18.90 | $18.50 | $18.85 | 2 089 780 |
| 2023-04-24 | $18.99 | $19.03 | $18.76 | $18.80 | 1 351 800 |
| 2023-04-21 | $18.98 | $19.03 | $18.83 | $19.01 | 2 489 725 |
| 2023-04-20 | $19.06 | $19.07 | $18.83 | $18.91 | 1 586 108 |
| 2023-04-19 | $19.13 | $19.29 | $19.10 | $19.16 | 1 266 891 |
| 2023-04-18 | $19.72 | $19.72 | $19.03 | $19.14 | 1 945 900 |
| 2023-04-17 | $19.50 | $19.82 | $19.44 | $19.75 | 3 255 399 |
| 2023-04-14 | $19.58 | $19.69 | $19.39 | $19.46 | 1 657 167 |
| 2023-04-13 | $19.48 | $19.92 | $19.45 | $19.64 | 2 486 333 |
| 2023-04-12 | $20.20 | $20.20 | $19.46 | $19.49 | 2 248 250 |
| 2023-04-11 | $20.11 | $20.32 | $20.04 | $20.08 | 3 234 541 |
| 2023-04-10 | $20.45 | $20.48 | $19.89 | $20.11 | 3 190 535 |
| 2023-04-06 | $19.85 | $20.56 | $19.76 | $20.48 | 3 975 458 |
| 2023-04-05 | $19.60 | $20.07 | $19.56 | $19.89 | 3 412 639 |
| 2023-04-04 | $19.48 | $19.58 | $19.31 | $19.55 | 1 806 467 |
| 2023-04-03 | $19.35 | $19.65 | $19.27 | $19.48 | 2 289 527 |
| 2023-03-31 | $18.95 | $19.49 | $18.88 | $19.41 | 3 287 090 |
| 2023-03-30 | $19.17 | $19.21 | $18.81 | $18.83 | 2 840 327 |
| 2023-03-29 | $18.77 | $19.24 | $18.77 | $19.19 | 3 024 591 |
| 2023-03-28 | $18.58 | $18.80 | $18.51 | $18.77 | 1 814 164 |
| 2023-03-27 | $18.51 | $18.79 | $18.46 | $18.66 | 2 596 370 |
| 2023-03-24 | $18.27 | $18.52 | $17.90 | $18.48 | 8 616 942 |
| 2023-03-23 | $18.42 | $18.52 | $18.11 | $18.33 | 2 871 802 |
About Exelixis
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CA... EXEL Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
